明尼苏达大学免疫抑制的发展历程。
Evolution of immunosuppression at the University of Minnesota.
作者信息
Matas A J, Sutherland D E R, Najarian J S
机构信息
Department of Surgery, University of Minnesota, Minneapolis, MN, USA.
出版信息
Transplant Proc. 2004 Mar;36(2 Suppl):64S-70S. doi: 10.1016/j.transproceed.2004.01.062.
Immunosuppressive protocols at the University of Minnesota have evolved from identical immunosuppression for all recipients (prednisone, azathioprine, and antilymphocyte globulin) to differing protocols for living (triple therapy) and cadaver (sequential therapy) donor recipients, and then to our current protocol in which all recipients receive induction therapy with rapid discontinuation of prednisone. At the same time, progress has been made in the prevention and treatment of cytomegalovirus infection along with numerous parallel improvements in patient care, including in anesthesia, dialysis, and intensive care unit care. The net result has been an incremental improvement in recipient and graft survival.
明尼苏达大学的免疫抑制方案已从对所有受者采用相同的免疫抑制方法（泼尼松、硫唑嘌呤和抗淋巴细胞球蛋白），发展为针对活体供者受者（三联疗法）和尸体供者受者采用不同方案（序贯疗法），进而发展为我们目前的方案，即所有受者均接受诱导治疗并迅速停用泼尼松。与此同时，在巨细胞病毒感染的预防和治疗方面取得了进展，同时在患者护理的许多方面也有了并行的改进，包括麻醉、透析和重症监护病房护理。最终结果是受者和移植物存活率逐步提高。
Zotero 插件